neurotherapeutic potential of CRF 1 antagonists. Our hypothesis is that CRF antagonists may be valuable in specific psychiatric disorders in which stress is a dynamic rather than chronic condition. More explicitly, we suggest that CRF 1 antagonists in psychiatry may particularly be useful in post-traumatic stress disorder (PTSD), panic disorder, and addiction.
Non-peptide CRF 1 antagonists consistently produce anxiolytic-like effects in certain animal models, such as conditioned freezing, defensive burying, acoustic startle responding, the open field, the elevated plus maze, the light-dark box, the defensive withdrawal test, and the social interaction test. A CRF 1 antagonist (R317573/JNJ19567470/CRA5626) also recently showed activity in rodent (Shekhar et al, 2011) and human (Bailey et al, 2011) panic models. These models reflect a dynamic, active response to an acute stressor and, from a face validity perspective, may reflect more the symptoms of specific subtypes of anxiety disorders rather than of generalized anxiety disorder. Indeed, CRF 1 antagonists exhibited weak activity in punished drinking and punished crossing conflict models, unlike g-aminobutyric acid anxiolytics. Despite initial positive results, small-molecule CRF 1 antagonists have not consistently shown efficacy in animal models of antidepressant activity (Zorrilla and Koob, 2010) .
CRF 1 antagonists also reduce the activation of brain stress systems in models of addiction, supporting the therapeutic potential of CRF 1 antagonists for drug dependence. Hypothalamic-pituitary adrenl-axis and extrahypothalamic CRF systems are activated during acute withdrawal from all major substances of abuse in animals. CRF antagonists blocked anxiogenic-like responses to withdrawal from cocaine, alcohol, nicotine, cannabinoids, and palatable food and blocked the development of or reduced already escalated drug selfadministration in addiction models (for details and references, see Koob and Zorrilla, 2010; Boyson et al, 2011) . CRF 1 antagonists also blocked stressinduced reinstatement of heroin-, cocaine-, nicotine-, alcohol-, and palatable food-seeking behavior and stress-induced reactivation of conditioned place preference for opioids and cocaine (Koob and Zorrilla, 2010) .
No CRF 1 antagonist has successfully completed a Phase III trial. R121919 and PF-00572778 were abandoned due to liver enzyme elevations (NCT00580190). The development of ONO-2333 Ms (NCT00514865) and CP-316,311 were halted because of negative efficacy in double-blind, placebo-controlled trials for major depression (Zorrilla and Koob, 2010 The neuropathology of schizophrenia is substantial in scope and complexity. In patients, structural abnormalities in about 20 brain regions span wide swaths of cortical and subcortical tissue, reflecting processes presumably well advanced at birth. Roughly half as many regions are abnormal in unaffected relatives (cf. Swerdlow, 2011) . Within any region, laminar synaptic and cellular arrangements
